Quotient and Bend discuss new collaboration at AAPS

By Gareth Macdonald and Claire Videau

- Last updated on GMT

Related tags: Clinical trial, Contract research organization

Quotient Clinical and Bend Research have teamed up to tackle solubility issues in early clinical development.

Outsourcing-pharma spoke with Quotient Clinical managing director Mark Egerton and Bend Research CEO Rod Ray, who predicted that combining the former’s trial design capabilities with the latter’s formulation technology, will offer customers a faster way to bring candidates to trial.

"Poorly soluble compounds are becoming ever more prevalent in the industry’s pipeline, and we have many customers who require formulation help to advance such problematic compounds,”​ explained Egerton.

He said Bend’s formulation expertise provides a “reliable, rapid and efficient drug formulation platform."

Ray agreed that Quotient’s “RapidFACT provides our clients with a game-changing advantage in advancing their compounds."

The deal marks the latest stage in Quotient Clinical’s development, which began in 2009 with parent company, Quotient Bioresearch’s acquisition of Charles River Laboratories’ early-stage clinical research facility in Edinburgh, Scotland.

It is also the second collaboration Bend has formed in as many months following a deal with US contract research organisation (CRO), PPD in October.

Related news

Show more

Related products

Flow Cytometry Services

Flow Cytometry Services

Q2 Solutions | 01-Jun-2020 | Data Sheet

We are an established leader in flow cytometry services for clinical trials. Our technologies and solutions meet the growing global demand for enhanced...

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Related suppliers

Follow us

Products

View more

Webinars